|
|
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with
brain metastases from solid tumors: a Hellenic Cooperative Oncology
Group (HeCOG) Phase II study Christos Christodoulou,
Dimitrios Bafaloukos, Helen Linardou,
Gerassimos Aravantinos, Aristotelis Bamias,
Maria Carina, George Klouvas and
Dimosthenis Skarlos
'Henry Dunant' Hospital, Athens, Greece
[C.C., G.K., D.S.]. Metropolitan Hospital, Greece [D.B., H.L.]. 'Agioi Anargiroi' Cancer Hospital, Athens
[G.A.]. University of Ioannina Medical School,
Ioannina [A.B.]. Aristotle University of Thessaloniki
Medical School, Thessaloniki, Greece [M.C.].
Correspondence to: Christos Christodoulou,
Email: hecogiat@otenet.gr, Phone: +30-210-69-72913/72508, Fax: +30-210-69-72607.
Purpose. To evaluate the efficacy of temozolomide (TMZ)
combined with cisplatin (CDDP) in terms of response rate, time to
progression (TTP) and overall survival (OS), as well as the
tolerability of the regimen in patients with brain metastases from
solid tumors.
Patients and methods. Patients (n=32) with brain
metastases were treated with TMZ 150 mg/m2/day
(chemotherapy-pretreated) or 200 mg/m2/day
(chemotherapy-naïve) for 5 days, combined with CDDP 75 mg/m2on
day 1, every 28 days.
Primary tumor sites included breast cancer (n=15), lung cancer
(n=12) and other (n=5).
Twenty-seven patients had
received prior chemotherapy for extracranial disease and 17 had prior
radiotherapy to the brain.
Results. One patient (3.1%) with non-small cell lung cancer
(NSCLC) achieved complete response.
Nine patients (28.1%; six with
breast cancer, two with melanoma and one with NSCLC) achieved a
partial response and five patients (16%) had stable disease.
Median OS
was 5.5 months
and median TTP 2.9 months.
One patient died from
septicemia/neutropenic fever.
Grade III–IV toxicities included
anemia (9%), leukopenia (6%), thrombocytopenia (3%), renal toxicity
(3%), headache (3%), fatigue (3%), nausea (3%), vomiting (3%), and
alopecia (6%).
Conclusions. TMZ combined with CDDP is an active and
well-tolerated combination in patients with brain metastases from
solid tumors.
Keywords: brain
metastases - breast cancer - cisplatin - lung
cancer - temozolomide
This work has been presented in part at the 27th
Congress of European Society for Medical Oncology, Nice, October 2002.
© Springer 2005
Source: http://springerlink.metapress.com/openurl.asp?genre=article&eissn=1573-7373&volume=71&issue=1&spage=61
DOI: http://dx.doi.org/10.1007/s11060-004-9176-0
|
